Paul Tudor Jones Biogen Inc. Call Options Transaction History

Tudor Investment Corp Et Al

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$189.07 - $236.8 $775,187 - $970,880	-4,100 Reduced 34.75%	7,700 $1.49 Million
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $1.35 Million - $1.68 Million	7,100 Added 151.06%	11,800 $2.74 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $169,616 - $214,167	800 Added 20.51%	4,700 $1.01 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $868,101 - $1.04 Million	3,900 New	3,900 $1.01 Million

1,036

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.